Additionally, BET inhibition, particularly targeting Bromodomain containing 4 (BRD4), enhances MHC‐I expression and CD8+ T cell‐mediated antitumour immunity in head and neck squamous cell carcinoma (HNSCC). This evidence concerns the gene CD8A and head and neck squamous cell carcinoma.